Clinical trials: Urinary Bladder Diseases
Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current…
- Trial name
- KEYNOTE-B15 (NCT04700124)
- Testing
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND
- Where
- 188 sites in United States, Argentina and 27 more
- Volunteers
- 808 people
- Sponsor
- Merck Sharp & Dohme LLC
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Bladder Cancer
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
This study, through a clinical controlled trial, compares the one-year, two-year, and three-year overall survival rates of patients in the treatment group guided by organoid drug sensitivity intervention with those of patients…
- Trial name
- NCT07379268
- Testing
- Organoid culture
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Qilu Hospital of Shandong University
Bladder Cancer
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.
- Trial name
- NCT03125460
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 424 people
- Sponsor
- Cepheid
Urinary Bladder Diseases, Urinary Bladder Neoplasms
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
The study is designed to compare the efficacy and safety of 2 treatment types for the prevention of tumor recurrence of superficial bladder cancer: 1. A combination of bladder wall heating and local chemotherapy (Synergo) 2.
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urinary Bladder Cancer, Malignant Tumor of Urinary Bladder
- Trial name
- NCT00384891
- Testing
- Synergo + MMC, Bacillus Calmette-Guérin
- Where
- 8 sites in Austria, Israel and 2 more
- Volunteers
- 190 people
- Sponsor
- Medical Enterprises Europe B.V.
Parkinson's Disease, Multiple System Atrophy
Botulinum A Toxin in Patients With Parkinson's Disease
The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Detrusor Overactivity
- Trial name
- Botox-PD (NCT00822913)
- Testing
- Intravesical injection of Botulinum A toxin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
Urge Incontinence, Urgency-frequency Syndrome
Percutaneous Nerve Evaluation Trial Time
Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998.
- Conditions
- Urge Incontinence, Urgency-frequency Syndrome, Overactive Bladder
- Trial name
- NCT06226220
- Testing
- Sacral neuromodulation
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Bladder Cancer
CD155 in Bladder Cancer
This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.
- Trial name
- NCT03789682
- Testing
- Adjuvant chemotherapy
- Where
- China
- Volunteers
- 151 people
- Sponsor
- Fudan University
Bladder Cancer
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
This trial is a randomized, multi-center, non-inferiority study comparing observation versus immediate surgery for low grade, noninvasive bladder cancer.
- Trial name
- NCT02700724
- Testing
- Immediate Surgery, Observation, Surveillance Cystoscopy and Urinary Cytology
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt University Medical Center
Cholangiocarcinoma Non-resectable, Gall Bladder Cancer
Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
The goal of this clinical randomized controlled trial is to perform primary percutaneous stenting (PPS) in patients with malignant hilar biliary obstruction (MHBO).
- Conditions
- Cholangiocarcinoma Non-resectable, Gall Bladder Cancer, Liver Metastasis, Malignant Hilar Stricture
- Trial name
- TESLA RCT (NCT06671418)
- Testing
- Primary percutaneous stenting (PPS), Endoscopic biliary drainage
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Erasmus Medical Center
Metastatic Renal Cell Carcinoma, Genitourinary Cancer (Bladder, Prostate or Testicular)
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
The primary objective is to evaluate methods for AGS-003 production from surgical (stage I) and metastatic biopsy (stage II) Renal Cell Carcinoma (RCC) and a small subset of other GU cancers (expansion cohort) specimens using…
- Trial name
- NCT02026960
- Testing
- RNA extraction and amplification from biopsy specimens
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Duke University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022191
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 234 sites in United States, Australia and 14 more
- Volunteers
- 608 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Carcinoma of Urinary Bladder, Invasive
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
The purpose of this study is to evaluate the safety of intravesical instillation of TC-3 Hydrogel disposable device for retention of mitomycin C chemotherapeutic drug in the urinary bladder.
- Trial name
- NCT01648010
- Testing
- TC-3 gel, TC-3 gel mixed with Mitomycin C (MMC)
- Where
- 3 sites in Israel
- Volunteers
- 7 people
- Sponsor
- UroGen Pharma Ltd.
Cancer, Immunotherapy
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or…
- Conditions
- Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
- Trial name
- ELEPHAS-05 (NCT07327489)
- Testing
- Biopsy
- Where
- 8 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Elephas
Bladder Cancer
Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002490
- Testing
- BCG vaccine, mitomycin C, radiation therapy
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Muscle Invasive Bladder Carcinoma
FL- 101 Study in Non-Metastatic MIBC
A pilot window of opportunity study of FL-101 in patients with non-metastatic MIBC who are eligible for radical cystectomy (RC) but are ineligible for, or decline, cisplatin-based neoadjuvant therapy.
- Trial name
- NCT05395260
- Testing
- FL-101
- Sponsor
- Flame Biosciences
Bladder Cancer
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which will increase their chances…
- Trial name
- NCT00918008
- Testing
- Blood draw
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals